Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
NOVATO, Calif., April 28, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, May 4, 2017 at 5pm ET to discuss first quarter 2017 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 12422215. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
